Skip to content

Study · Case report or series · n = 1 · 2026

7 results

Glucagon-like peptide-1 receptor agonists as adjunctive therapy in refractory hypertriglyceridemia following recurrent pancreatitis.

Miura D, Nicholls S, Joham AE, Braude M, Tay CT

JCEM case reports16 Sept 2026

PMID42750924 (opens in a new tab)DOI10.1210/jcemcr/luag274 (opens in a new tab)PepBankPUB-42750924
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a man with refractory hypertriglyceridemia and recurrent pancreatitis, semaglutide achieved sustained triglyceride normalization to 213 mg/dL.

    In plain wordsIn one man with very high triglycerides and repeated pancreatitis, semaglutide was followed by triglycerides falling to a normal level.

    Peptide
    Semaglutide
    Outcome
    DecreaseTriglyceride normalization
    Study

    n = 1

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Triglycerides
    213 mg/dL
    after semaglutide

    Source sentences

    Summary
    This achieved sustained triglyceride normalization to 213 mg/dL (SI: 2.4 mmol/L)
    2 context sentences
    Summary · context
    A 39-year-old Chinese man was first evaluated at a multidisciplinary metabolic dysfunction-associated liver disease clinic following 6 episodes of hypertriglyceridemia-induced pancreatitis over 9 years despite maximal therapy with statins, fibrates, and omega-3 fatty acids.
    Summary · context
    Despite historical safety concerns regarding glucagon-like peptide-1 receptor agonists in prior pancreatitis, semaglutide was cautiously initiated.
  2. 02HumanCase report or seriesEfficacy outcome

    In a man with refractory hypertriglyceridemia, weight loss occurred after semaglutide initiation.

    In plain wordsIn one man with very high triglycerides, weight loss followed the start of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    weight loss
    2 context sentences
    Summary · context
    A 39-year-old Chinese man was first evaluated at a multidisciplinary metabolic dysfunction-associated liver disease clinic following 6 episodes of hypertriglyceridemia-induced pancreatitis over 9 years despite maximal therapy with statins, fibrates, and omega-3 fatty acids.
    Summary · context
    Despite historical safety concerns regarding glucagon-like peptide-1 receptor agonists in prior pancreatitis, semaglutide was cautiously initiated.
  3. 03HumanCase report or seriesEfficacy outcome

    In a man with poorly controlled diabetes, glycemic improvement occurred after semaglutide initiation.

    In plain wordsIn one man with poorly controlled diabetes, blood sugar control improved after semaglutide was started.

    Peptide
    Semaglutide
    Outcome
    Not applicableGlycemic control
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    glycemic improvement
    2 context sentences
    Summary · context
    A 39-year-old Chinese man was first evaluated at a multidisciplinary metabolic dysfunction-associated liver disease clinic following 6 episodes of hypertriglyceridemia-induced pancreatitis over 9 years despite maximal therapy with statins, fibrates, and omega-3 fatty acids.
    Summary · context
    Despite historical safety concerns regarding glucagon-like peptide-1 receptor agonists in prior pancreatitis, semaglutide was cautiously initiated.
  4. 04HumanCase report or seriesEfficacy outcome

    In a man with recurrent hypoglycemia, hypoglycemia resolved after semaglutide initiation.

    In plain wordsIn one man with repeated low blood sugar, the low blood sugar episodes stopped after semaglutide was started.

    Peptide
    Semaglutide
    Outcome
    DecreaseHypoglycemia
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    hypoglycemia resolution
    2 context sentences
    Summary · context
    A 39-year-old Chinese man was first evaluated at a multidisciplinary metabolic dysfunction-associated liver disease clinic following 6 episodes of hypertriglyceridemia-induced pancreatitis over 9 years despite maximal therapy with statins, fibrates, and omega-3 fatty acids.
    Summary · context
    Despite historical safety concerns regarding glucagon-like peptide-1 receptor agonists in prior pancreatitis, semaglutide was cautiously initiated.
  5. 05HumanCase report or seriesEfficacy outcome

    In a man with steatotic liver disease and moderate fibrosis, liver elastography parameters improved after semaglutide initiation.

    In plain wordsIn one man with fatty liver disease, liver stiffness scans improved after semaglutide was started.

    Peptide
    Semaglutide
    Outcome
    Not applicableLiver elastography parameters
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    improved liver elastography parameters
    2 context sentences
    Summary · context
    A 39-year-old Chinese man was first evaluated at a multidisciplinary metabolic dysfunction-associated liver disease clinic following 6 episodes of hypertriglyceridemia-induced pancreatitis over 9 years despite maximal therapy with statins, fibrates, and omega-3 fatty acids.
    Summary · context
    Despite historical safety concerns regarding glucagon-like peptide-1 receptor agonists in prior pancreatitis, semaglutide was cautiously initiated.
  6. 06HumanCase report or seriesEfficacy outcome

    In a man with poorly controlled diabetes, insulin could be stopped after semaglutide initiation.

    In plain wordsIn one man with diabetes, insulin could be stopped after semaglutide was started.

    Peptide
    Semaglutide
    Outcome
    DecreaseInsulin requirement
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    insulin cessation
    2 context sentences
    Summary · context
    A 39-year-old Chinese man was first evaluated at a multidisciplinary metabolic dysfunction-associated liver disease clinic following 6 episodes of hypertriglyceridemia-induced pancreatitis over 9 years despite maximal therapy with statins, fibrates, and omega-3 fatty acids.
    Summary · context
    Despite historical safety concerns regarding glucagon-like peptide-1 receptor agonists in prior pancreatitis, semaglutide was cautiously initiated.
  7. 07HumanCase report or seriesSafety outcome

    In a man with six prior episodes of hypertriglyceridemia-induced pancreatitis, pancreatitis did not recur on semaglutide.

    In plain wordsIn one man with repeated pancreatitis in the past, pancreatitis did not return while on semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeRecurrence of pancreatitis
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    without pancreatitis recurrence
    2 context sentences
    Summary · context
    A 39-year-old Chinese man was first evaluated at a multidisciplinary metabolic dysfunction-associated liver disease clinic following 6 episodes of hypertriglyceridemia-induced pancreatitis over 9 years despite maximal therapy with statins, fibrates, and omega-3 fatty acids.
    Summary · context
    Despite historical safety concerns regarding glucagon-like peptide-1 receptor agonists in prior pancreatitis, semaglutide was cautiously initiated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.